Skip to main content
main-content
Erschienen in: DNP – Die Neurologie & Psychiatrie 6/2019

02.12.2019 | Kopfschmerz und Migräne in der Pädiatrie | Zertifizierte Fortbildung

Migräne, Clusterkopfschmerz und Co

Multimodale Programme und neue Therapien gegen den Kopfschmerz

verfasst von: Univ. Prof. Dr. med. Andreas Straube, PD Dr. med. Ruth Ruscheweyh

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der dramatische Wissenszuwachs in den letzten zwei Dekaden hat zu einem besseren Verständnis von Kopfschmerzen beigetragen. Die Versorgung von Kopfschmerzpatienten konnte durch multimodale Behandlungsprogramme, die Entwicklung von Leitlinien und gezielte Weiterbildungen verbessert werden. Neue Optionen wie die CGRP-Antikörper, „small molecules“ gegen den CGRP-Rezeptor oder Stimulations-verfahren haben die Therapie von Kopfschmerzen nach vorne gebracht.
Literatur
1.
Zurück zum Zitat Wolff HG, Marcussen RM, Kunkle EC. Studies on headache; analysis of the contractile state of the cranial vascular tree in migraine. Trans Am Neurol Assoc. 1948;73(73 Annual Meet.):14–7 PubMed Wolff HG, Marcussen RM, Kunkle EC. Studies on headache; analysis of the contractile state of the cranial vascular tree in migraine. Trans Am Neurol Assoc. 1948;73(73 Annual Meet.):14–7 PubMed
2.
Zurück zum Zitat Blau J, Wolff HG: the man and his migraine. Cephalalgia. 2004 Mar;24(3):215–22 CrossRef Blau J, Wolff HG: the man and his migraine. Cephalalgia. 2004 Mar;24(3):215–22 CrossRef
3.
Zurück zum Zitat Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev. 2005 Jun;48(3):438–56 CrossRefPubMed Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev. 2005 Jun;48(3):438–56 CrossRefPubMed
4.
Zurück zum Zitat May A, Goadsby PJ. Substance P receptor antagonists in the therapy of migraine. Expert Opin Investig Drugs. 2001;10(4):673–8 CrossRefPubMed May A, Goadsby PJ. Substance P receptor antagonists in the therapy of migraine. Expert Opin Investig Drugs. 2001;10(4):673–8 CrossRefPubMed
6.
Zurück zum Zitat Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–6 CrossRefPubMed Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–6 CrossRefPubMed
7.
Zurück zum Zitat Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–10 CrossRefPubMed Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–10 CrossRefPubMed
8.
Zurück zum Zitat Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350 CrossRefPubMed Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350 CrossRefPubMed
9.
Zurück zum Zitat Straube A, Aicher B, Förderreuther S, Eggert T, Köppel J, Möller S, Schneider R, Haag G. Period prevalence of self-reported headache in the general population in Germany from 1995-2005 and 2009: results from annual nationwide population-based cross-sectional surveys. J Headache Pain. 2013;14(1):11 CrossRefPubMedPubMedCentral Straube A, Aicher B, Förderreuther S, Eggert T, Köppel J, Möller S, Schneider R, Haag G. Period prevalence of self-reported headache in the general population in Germany from 1995-2005 and 2009: results from annual nationwide population-based cross-sectional surveys. J Headache Pain. 2013;14(1):11 CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat McKenzie K, Murray A, Booth T. Do urban environments increase the risk of anxiety, depression and psychosis? An epidemiological study. J Affect Disord. 2013;150(3):1019–24 CrossRefPubMed McKenzie K, Murray A, Booth T. Do urban environments increase the risk of anxiety, depression and psychosis? An epidemiological study. J Affect Disord. 2013;150(3):1019–24 CrossRefPubMed
11.
Zurück zum Zitat Lehtinen V, Michalak E, Wilkinson C, Dowrick C, Ayuso-Mateos JL, Dalgard OS, Casey P, Vázquez-Barquero JL, Wilkinson G; ODIN Group. Urban-rural differences in the occurrence of female depressive disorder in Europe—evidence from the ODIN study. Soc Psychiatry Psychiatr Epidemiol. 2003;38(6):283–9 CrossRefPubMed Lehtinen V, Michalak E, Wilkinson C, Dowrick C, Ayuso-Mateos JL, Dalgard OS, Casey P, Vázquez-Barquero JL, Wilkinson G; ODIN Group. Urban-rural differences in the occurrence of female depressive disorder in Europe—evidence from the ODIN study. Soc Psychiatry Psychiatr Epidemiol. 2003;38(6):283–9 CrossRefPubMed
12.
Zurück zum Zitat Straube A, Ruscheweyh R. Epidemiologie von Kopfschmerzen über die Lebensspanne. Nervenheilkunde 2019; 38:735–739 CrossRef Straube A, Ruscheweyh R. Epidemiologie von Kopfschmerzen über die Lebensspanne. Nervenheilkunde 2019; 38:735–739 CrossRef
13.
Zurück zum Zitat Straube A, Pfaffenrath V, Ladwig KH, Meisinger C, Hoffmann W, Fendrich K, Vennemann M, Berger K. Prevalence of chronic migraine and medication overuse headache in Germany - the German DMKG headache study. Cephalalgia. 2010;30(2):207–13 CrossRefPubMed Straube A, Pfaffenrath V, Ladwig KH, Meisinger C, Hoffmann W, Fendrich K, Vennemann M, Berger K. Prevalence of chronic migraine and medication overuse headache in Germany - the German DMKG headache study. Cephalalgia. 2010;30(2):207–13 CrossRefPubMed
14.
Zurück zum Zitat Katsarava Z, Manack A, Yoon MS, Obermann M, Becker H, Dommes P, Turkel C, Lipton RB, Diener HC. Chronic migraine: classification and comparisons. Cephalalgia. 2011;31(5):520–9 CrossRefPubMed Katsarava Z, Manack A, Yoon MS, Obermann M, Becker H, Dommes P, Turkel C, Lipton RB, Diener HC. Chronic migraine: classification and comparisons. Cephalalgia. 2011;31(5):520–9 CrossRefPubMed
15.
Zurück zum Zitat Fendrich K, Vennemann M, Pfaffenrath V, Evers S, May A, Berger K, Hoffmann W. Headache prevalence among adolescents -the German DMKG headache study. Cephalalgia. 2007;27(4):347–54 CrossRefPubMed Fendrich K, Vennemann M, Pfaffenrath V, Evers S, May A, Berger K, Hoffmann W. Headache prevalence among adolescents -the German DMKG headache study. Cephalalgia. 2007;27(4):347–54 CrossRefPubMed
16.
Zurück zum Zitat Kröner-Herwig B, Heinrich M, Morris L. Headache in German children and adolescents: a population-based epidemiological study. Cephalalgia. 2007;27(6):519–27 CrossRefPubMed Kröner-Herwig B, Heinrich M, Morris L. Headache in German children and adolescents: a population-based epidemiological study. Cephalalgia. 2007;27(6):519–27 CrossRefPubMed
17.
Zurück zum Zitat Kröner-Herwig B. Headache in children and adolescents. Epidemiology, biopsychosocial correlates, and psychological treatment approaches]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(8):928–34 CrossRefPubMed Kröner-Herwig B. Headache in children and adolescents. Epidemiology, biopsychosocial correlates, and psychological treatment approaches]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(8):928–34 CrossRefPubMed
18.
Zurück zum Zitat Milde-Busch A, Blaschek A, Borggräfe I, von Kries R, Straube A, Heinen F. [Is there an association between the reduced school years in grammar schools and headache and other health complaints in adolescent students?]. Klin Padiatr. 2010;222(4):255–60 CrossRefPubMed Milde-Busch A, Blaschek A, Borggräfe I, von Kries R, Straube A, Heinen F. [Is there an association between the reduced school years in grammar schools and headache and other health complaints in adolescent students?]. Klin Padiatr. 2010;222(4):255–60 CrossRefPubMed
19.
Zurück zum Zitat Stovner Lj, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210 CrossRefPubMed Stovner Lj, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210 CrossRefPubMed
20.
Zurück zum Zitat Albers L, Kries RV, Straube A, Heinen F, Landgraf MN, Obermeier V, Ruscheweyh R. Age- and sex-specific first health care use for migraine in 2016 in children and adolescents from prospectively collected health insurance data in Germany. Cephalalgia. 2019;39(9):1156–63 CrossRefPubMed Albers L, Kries RV, Straube A, Heinen F, Landgraf MN, Obermeier V, Ruscheweyh R. Age- and sex-specific first health care use for migraine in 2016 in children and adolescents from prospectively collected health insurance data in Germany. Cephalalgia. 2019;39(9):1156–63 CrossRefPubMed
21.
Zurück zum Zitat Anttila P, Metsähonkala L, Sillanpää M. Long-term trends in the incidence of headache in Finnish schoolchildren. Pediatrics. 2006;117(6):e1197–201 CrossRefPubMed Anttila P, Metsähonkala L, Sillanpää M. Long-term trends in the incidence of headache in Finnish schoolchildren. Pediatrics. 2006;117(6):e1197–201 CrossRefPubMed
22.
Zurück zum Zitat Rozen TD, Swanson JW, Stang PE, McDonnell SK, Rocca WA. Increasing incidence of medically recognized migraine headache in a United States population. Neurolog. 1999;53(7):1468–73 CrossRef Rozen TD, Swanson JW, Stang PE, McDonnell SK, Rocca WA. Increasing incidence of medically recognized migraine headache in a United States population. Neurolog. 1999;53(7):1468–73 CrossRef
23.
Zurück zum Zitat Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Suppl. 7): 1–96 Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Suppl. 7): 1–96
24.
Zurück zum Zitat Diener HC, Gaul C, Jensen R, Göbel H, Heinze A, Silberstein SD. Integrated headache care. Cephalalgia. 2011;31(9):1039–47 CrossRefPubMed Diener HC, Gaul C, Jensen R, Göbel H, Heinze A, Silberstein SD. Integrated headache care. Cephalalgia. 2011;31(9):1039–47 CrossRefPubMed
25.
Zurück zum Zitat Felbinger J, Reinisch VM, Sostak P, Wallasch TM, Diener HC, Straube A. Anxiety and depression in headache patients. The example of managed care of chronic headache patients in Bavaria]. Schmerz. 2009;23(1):33–9 CrossRefPubMed Felbinger J, Reinisch VM, Sostak P, Wallasch TM, Diener HC, Straube A. Anxiety and depression in headache patients. The example of managed care of chronic headache patients in Bavaria]. Schmerz. 2009;23(1):33–9 CrossRefPubMed
26.
Zurück zum Zitat Gaul C, Brömstrup J, Fritsche G, Diener HC, Katsarava Z. Evaluating integrated headache care: a one-year follow-up observational study in patients treated at the Essen headache centre. BMC Neurol. 2011;11:124 CrossRefPubMedPubMedCentral Gaul C, Brömstrup J, Fritsche G, Diener HC, Katsarava Z. Evaluating integrated headache care: a one-year follow-up observational study in patients treated at the Essen headache centre. BMC Neurol. 2011;11:124 CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Gaul C, Visscher CM, Bhola R, Sorbi MJ, Galli F, Rasmussen AV, Jensen R (2011) Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache. J Headache Pain;12(5):511–9 CrossRefPubMedPubMedCentral Gaul C, Visscher CM, Bhola R, Sorbi MJ, Galli F, Rasmussen AV, Jensen R (2011) Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache. J Headache Pain;12(5):511–9 CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Marziniak M, Malzacher V, Förderreuther S, Jürgens T, Kropp P, May A, Straube A; Deutsche Migräne- und Kopfschmerzgesellschaft e. V. [Consensus paper of the German Migraine and Headache Society on the structure of headache care facilities in Germany]. Schmerz. 2014;28(2):128–34 CrossRefPubMed Marziniak M, Malzacher V, Förderreuther S, Jürgens T, Kropp P, May A, Straube A; Deutsche Migräne- und Kopfschmerzgesellschaft e. V. [Consensus paper of the German Migraine and Headache Society on the structure of headache care facilities in Germany]. Schmerz. 2014;28(2):128–34 CrossRefPubMed
30.
Zurück zum Zitat Ruscheweyh R, Dresler T, Scheidt J, Drescher J, Förderreuther S. Aktuelle Projekte: Das Kopfschmerzregister der DMKG. Nervenheilkunde 2019; 38: 728–734 CrossRef Ruscheweyh R, Dresler T, Scheidt J, Drescher J, Förderreuther S. Aktuelle Projekte: Das Kopfschmerzregister der DMKG. Nervenheilkunde 2019; 38: 728–734 CrossRef
31.
Zurück zum Zitat Diener HC, Gaul C, Kropp P et al. Therapie der Migräneattacke und Prophylaxe der Migräne. Leitlinie für Diagnostik und Therapie in der Neurologie. DGN 2018 Diener HC, Gaul C, Kropp P et al. Therapie der Migräneattacke und Prophylaxe der Migräne. Leitlinie für Diagnostik und Therapie in der Neurologie. DGN 2018
32.
Zurück zum Zitat Diener HC, Gaul C, Kropp P et al. Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln (Medication Overuse Headache = MOH). Leitlinie für Diagnostik und Therapie in der Neurologie. DGN 2018 Diener HC, Gaul C, Kropp P et al. Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln (Medication Overuse Headache = MOH). Leitlinie für Diagnostik und Therapie in der Neurologie. DGN 2018
33.
Zurück zum Zitat Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D’Alessandro R, De Ponti F, Poluzzi E. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015;35(2):118–31 CrossRefPubMed Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D’Alessandro R, De Ponti F, Poluzzi E. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015;35(2):118–31 CrossRefPubMed
34.
Zurück zum Zitat Scher AI, Rizzoli PB, Loder EW. Medication overuse headache: An entrenched idea in need of scrutiny. Neurology. 2017;89(12):1296–1304 CrossRefPubMed Scher AI, Rizzoli PB, Loder EW. Medication overuse headache: An entrenched idea in need of scrutiny. Neurology. 2017;89(12):1296–1304 CrossRefPubMed
35.
Zurück zum Zitat Friedman BW, Irizarry E, Solorzano C, Latev A, Rosa K, Zias E, Vinson DR, Bijur PE, Gallagher EJ. Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology. 2017;89(20):2075–82 CrossRefPubMedPubMedCentral Friedman BW, Irizarry E, Solorzano C, Latev A, Rosa K, Zias E, Vinson DR, Bijur PE, Gallagher EJ. Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology. 2017;89(20):2075–82 CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia. 2018;38(6):1081–92 CrossRefPubMed Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia. 2018;38(6):1081–92 CrossRefPubMed
37.
Zurück zum Zitat Loo LS, Ailani J, Schim J, Baygani S, Hundemer HP, Port M, Krege JH. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20(1):84 CrossRefPubMedPubMedCentral Loo LS, Ailani J, Schim J, Baygani S, Hundemer HP, Port M, Krege JH. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20(1):84 CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–45 CrossRefPubMed Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–45 CrossRefPubMed
39.
Zurück zum Zitat Lemmens J, De Pauw J, Van Soom T, Michiels S, Versijpt J, van Breda E, Castien R, De Hertogh W. The effect of aerobic exercise on the number of migraine days, duration and pain intensity in migraine: a systematic literature review and meta-analysis. J Headache Pain. 2019;20(1):16 CrossRefPubMedPubMedCentral Lemmens J, De Pauw J, Van Soom T, Michiels S, Versijpt J, van Breda E, Castien R, De Hertogh W. The effect of aerobic exercise on the number of migraine days, duration and pain intensity in migraine: a systematic literature review and meta-analysis. J Headache Pain. 2019;20(1):16 CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Kropp P, Meyer B, Dresler T, Fritsche G, Gaul C, Niederberger U, Förderreuther S, Malzacher V, Jürgens TP, Marziniak M, Straube A. [Relaxation techniques and behavioural therapy for the treatment of migraine: Guidelines from the German Migraine and Headache Society]. Schmerz. 2017;31(5):433–47 CrossRefPubMed Kropp P, Meyer B, Dresler T, Fritsche G, Gaul C, Niederberger U, Förderreuther S, Malzacher V, Jürgens TP, Marziniak M, Straube A. [Relaxation techniques and behavioural therapy for the treatment of migraine: Guidelines from the German Migraine and Headache Society]. Schmerz. 2017;31(5):433–47 CrossRefPubMed
41.
Zurück zum Zitat Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36 CrossRefPubMed Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36 CrossRefPubMed
42.
Zurück zum Zitat Ruscheweyh R, Förderreuther S, Gaul C, Gendolla A, Holle-Lee D, Jürgens T, Neeb L, Straube A. [Treatment of chronic migraine with botulinum neurotoxin A: Expert recommendations of the German Migraine and Headache Society]. Nervenarzt. 2018;89(12):1355–64 CrossRefPubMed Ruscheweyh R, Förderreuther S, Gaul C, Gendolla A, Holle-Lee D, Jürgens T, Neeb L, Straube A. [Treatment of chronic migraine with botulinum neurotoxin A: Expert recommendations of the German Migraine and Headache Society]. Nervenarzt. 2018;89(12):1355–64 CrossRefPubMed
43.
Zurück zum Zitat Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377(22):2123–32 CrossRefPubMed Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377(22):2123–32 CrossRefPubMed
44.
Zurück zum Zitat Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018;75(9):1080–88 CrossRefPubMedPubMedCentral Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018;75(9):1080–88 CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018;319(19):1999–2008 CrossRefPubMed Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018;319(19):1999–2008 CrossRefPubMed
46.
Zurück zum Zitat Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211 CrossRef Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211 CrossRef
48.
Zurück zum Zitat Gaul C, Diener HC, Silver N, Magis D, Reuter U, Andersson A, Liebler EJ, Straube A; PREVA Study Group. Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Cephalalgia. 2016;36(6):534–46 CrossRefPubMed Gaul C, Diener HC, Silver N, Magis D, Reuter U, Andersson A, Liebler EJ, Straube A; PREVA Study Group. Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Cephalalgia. 2016;36(6):534–46 CrossRefPubMed
49.
Zurück zum Zitat Goadsby PJ, de Coo IF, Silver N, Tyagi A, Ahmed F, Gaul C, Jensen RH, Diener HC, Solbach K, Straube A, Liebler E, Marin JC, Ferrari MD; ACT2 Study Group. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia. 2018;38(5):959–69 CrossRefPubMed Goadsby PJ, de Coo IF, Silver N, Tyagi A, Ahmed F, Gaul C, Jensen RH, Diener HC, Solbach K, Straube A, Liebler E, Marin JC, Ferrari MD; ACT2 Study Group. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia. 2018;38(5):959–69 CrossRefPubMed
50.
Zurück zum Zitat Kamm A, Ruscheweyh R, Straube A. Das reversible zerebrale Vasokonstriktionssyndrom. Als Ursache von Donnerschlagkopfschmerzen unterschätzt? Nervenheilkunde 2018;37:43–49 CrossRef Kamm A, Ruscheweyh R, Straube A. Das reversible zerebrale Vasokonstriktionssyndrom. Als Ursache von Donnerschlagkopfschmerzen unterschätzt? Nervenheilkunde 2018;37:43–49 CrossRef
Metadaten
Titel
Migräne, Clusterkopfschmerz und Co
Multimodale Programme und neue Therapien gegen den Kopfschmerz
verfasst von
Univ. Prof. Dr. med. Andreas Straube
PD Dr. med. Ruth Ruscheweyh
Publikationsdatum
02.12.2019
Verlag
Springer Medizin
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 6/2019
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-019-2296-3